

Table DS1 Standardised domain scores using the AGREE instrument.

Author (year)	Country	Scope and purpose	Stakeholder involvement	Standardised domain score %			
				Rigour of development	Clarity and presentation	Application	Editorial independence
ADA/APA (2004) ⁷⁵	USA	81.5	27.8	38.1	58.3	40.7	55.6
Marder et al (2004) ⁸⁶	USA	51.9	36.1	49.2	58.3	85.2	100
Melkerson et al (2004) ⁸⁷	Sweden	33.3	16.7	15.9	25.0	3.7	0
Lambert et al (2004) ⁸⁴	Australia	51.9	75	36.5	63.9	51.9	66.7
Dinan et al (2004) ⁸¹	UK	74.1	33.3	20.6	50.0	40.7	5.6
De Nayer et al (2005) ⁸⁰	Belgium	66.7	36.1	28.6	61.1	55.6	27.8
Poulin et al (2005) ⁸⁸	Canada	44.4	16.7	27.0	55.6	18.5	33.3
Amati et al (2006) ⁷⁶	Italy	37.0	25	25.4	47.2	22.2	0
Lefevre et al (2006) ⁸⁵	France	51.9	2.8	9.5	16.7	11.1	0
Usher et al (2006) ⁹²	Australia	37.0	16.7	14.3	30.6	11.1	0
Barnett et al (2007) ⁷⁷	UK	81.5	27.8	42.9	61.1	66.7	55.6
Cahn et al (2008) ⁷⁸	Netherlands	48.2	22.2	30.2	50.0	37.0	72.2
Elkis et al (2008) ⁸²	Brazil	33.3	25.5	21	52.8	22.2	83.3
Saiz et al (2008) ⁸⁹	Spain	66.7	27.8	69.8	50.0	25.9	16.7
Salokangas et al (2008) ⁹⁰	Finland	33.3	22.2	19.1	30.6	22.2	0
Saravane et al (2008) ⁹¹	France	70.4	27.8	20.6	58.3	81.5	5.6
De Hert et al (2009) ⁷⁹	Europe	81.5	36.1	47.6	75.0	63.0	100
Gotheffors et al (2010) ⁸³	Sweden	70.4	75	36.5	66.7	59.3	0
Mean score^a		56.4	30.6	30.7	50.6	39.9	34.6

a. Average standardised domain scores from pooled results from all the guidelines.

Table DS2 Guideline development process

Author (year)	Year development	Clear method	Consensus model	Review literature	Review Process	Industry involvement	Conflict of interest statement
ADA/APA (2004) ⁷⁵	2003		x	x		x	x
Marder et al (2004) ⁸⁶	2004	x	x	x	Systematic		x
Melkerson et al (2004) ⁸⁷	2003			x			
Lambert et al (2004) ⁸⁴	2004		x	x	Levels of evidence	x	
Dinan et al (2004) ⁸¹	2003				*	x	
De Nayer et al (2005) ⁸⁰	2005	(x)	x	x	Systematic		x
Poulin et al (2005) ⁸⁸	2005			x		x	
Amati et al (2006) ⁷⁶	2006		x	x			
Lefevre et al (2006) ⁸⁵	2006						
Usher et al (2006) ⁹²	2006			x			
Barnett et al (2007) ⁷⁷	2007	x	x	x		x	x
Cahn et al (2008) ⁷⁸	2008		x	x		x	(x)
Elkis et al (2008) ⁸²	2007		x	x			x
Saiz et al (2008) ⁸⁹	2008	x	x	x	Systematic, MA	x	
Salokangas et al (2008) ⁹⁰	2008						
Saravane et al (2008) ⁹¹	2008			x		x	
De Hert et al (2009) ⁷⁹	2008	x	x	x	Systematic		x
Gotheffors et al (2010) ⁸³	2009	x	x	x	Systematic		
Fulfilling criterion n (%)		6 (33%)	11 (61%)	14 (78%)	6 (33%)	8 (44%)	7 (39%)

Table DS2 Guideline development process (*continued*).

Author (year)	Official societies	Different disciplines	Target schizophrenia	Target also other SMI	Target young patients mentioned
ADA/APA (2004) ⁷⁵	x	x	x	(x)	x
Marder et al (2004) ⁸⁶		x	x		
Melkerson et al (2004) ⁸⁷		x	x		
Lambert et al (2004) ⁸⁴		x	(x)		
Dinan et al (2004) ⁸¹		x	x		
De Nayer et al (2005) ⁸⁰		x	x	x	
Poulin et al (2005) ⁸⁸		x	x	x	
Amati et al (2006) ⁷⁶			x		
Lefevre et al (2006) ⁸⁵			x		
Usher et al (2006) ⁹²			x		
Barnett et al (2007) ⁷⁷		x	x		
Cahn et al (2008) ⁷⁸	x	x	x	x	x
Elkis et al (2008) ⁸²	x	x	x	x	
Saiz et al (2008) ⁸⁹	x	x	x		
Salokangas et al (2008) ⁹⁰	x	x	x		
Saravane et al (2008) ⁹¹		x	x		
De Hert et al (2009) ⁷⁹	x	x	x	x	x
Gotheffors et al (2010) ⁸³	x	x	x	x	x
Fulfilling criterion n (%)	7 (39%)	15 (83%)	18 (100%)	7 (39%)	4 (22%)

(x), incomplete or vague; * in the same issue of the journal systematic reviews were published; SMI, severe mental illness.

Table DS3 Assessment of risk factors in the clinical practice guidelines

Author (year)	Personal history	Familial history	Physical examination	Alcohol	Substance use	Smoking	Physical activity	Diet
ADA/APA (2004) ⁷⁵	x	x						
Marder et al (2004) ⁸⁶	x	x						
Melkerson et al (2004) ⁸⁷		x			x	x		
Lambert et al (2004) ⁸⁴	x	x			x	x	x	
Dinan et al (2004) ⁸¹	x	x						
De Nayer et al (2005) ⁸⁰	x	x	x	x	x	x	x	x
Poulin et al (2005) ⁸⁸	x	x	x		x	x	x	x
Amati et al (2006) ⁷⁶	x	x						
Lefevre et al (2006) ⁸⁵		x	x		x			
Usher et al (2006) ⁹²	x	x	x					
Barnett et al (2007) ⁷⁷	x	x			x	x	x	x
Cahn et al (2008) ⁷⁸	x	x	x					
Elkis et al (2008) ⁸²	x	x				x	x	
Saiz et al (2008) ⁸⁹	x	x	x	x	x	x		
Salokangas et al (2008) ⁹⁰			x					
Saravane et al (2008) ⁹¹	x	x	x	x	x	x	x	x
De Hert et al (2009) ⁷⁹	x	x	x	x	x	x	x	x
Gotheffors et al (2010) ⁸³	x	x	x		x	x	x	x
Fulfilling criterion n (%)	15 (83%)	17 (94%)	10 (56%)	4 (22%)	4 (22%)	10 (56%)	9 (50%)	7 (39%)

Table DS4 Recommendations about the screening and monitoring.

Author (year)	Frequency dependent on AP choice	Frequency dependent on start AP	Frequency dependent on RF	Psychiatrist responsibility	Mental health specialist responsibility	GP responsibility
ADA/APA (2004) ⁷⁵		x	x	x		
Marder et al (2004) ⁸⁶	x	x	x		x	
Melkerson et al (2004) ⁸⁷	x		x	Unclear		
Lambert et al (2004) ⁸⁴		x	x	x		x
Dinan et al (2004) ⁸¹		x	x		x	x
De Nayer et al (2005) ⁸⁰	x	x	x	x		x
Poulin et al (2005) ⁸⁸		x	x		x	
Amati et al (2006) ⁷⁶		x	x	x		
Lefevre et al (2006) ⁸⁵		x		x		
Usher et al (2006) ⁹²		x	x	Unclear		
Barnett et al (2007) ⁷⁷		x		x	x	
Cahn et al (2008) ⁷⁸		x	x	x		
Elkis et al (2008) ⁸²		x	x	x		
Saiz et al (2008) ⁸⁹	x	x	x	x		
Salokangas et al (2008) ⁹⁰				x		
Saravane et al (2008) ⁹¹		x	x	x		x
De Hert et al (2009) ⁷⁹		x	x	x	x	x
Gotheffors et al (2010) ⁸³	x	x	x	x	x	x
Fulfilling criterion n (%)	5 (28%)	16 (89%)	15 (83%)	13 (72%)	6 (33%)	6 (33%)

AP, antipsychotic; RF, risk factors for cardiovascular disease and diabetes; GP, general practitioner.

Table DS5 Recommended for metabolic measurements and proposed timing of assessments.

Author (year)	BMI	Cut-off values	Waist	Cut-off values	Frequency	BP	Cut-off values	Frequency	FGLU	Cut-off values	Frequency	Other glucose measurements
ADA/APA (2004) ⁷⁵	x	x	x		bl 4w 8w 12w quart	x	x	bl 12w ann	x	x (100)	bl 12w ann	
Marder et al (2004) ⁸⁶	x	x	x	x	bl every visit for 6m quart				x	x (100)	start. 4m ann	(NF) (HbA1c) (OGTT)
Melkerson et al (2004) ⁸⁷	x	x							x		unclear	(NF)
Lambert et al (2004) ⁸⁴	x	x	x		bl quart	x		bl 6monthly	x	x (100)	bl 3m 6m 2xyear	NF OGTT
Dinan et al (2004) ⁸¹									x	x (110)	bl 4m after initiation. ann when normal	NF HbA1c (OGTT)
De Nayer et al (2005) ⁸⁰	x	x	x	x	weekly hosp monthly	x	x	bl quart	x	x (100)	bl 6 w 3m quart	(NF) OGTT
Poulin et al (2005) ⁸⁸	x	x	x	x	bl 1m 3 m 6m ann				x	x (100)	bl 1m 3 m 6 m ann	NF OGTT
Amati et al (2006) ⁷⁶	x	x	x	x	Bl 4w 8w 12w quart	x	x	Bl 12w ann	x	x (100)	bl 12 w ann	NF (HbA1c)
Lefevre et al (2006) ⁸⁵	x	x	x	x	bl 4w 8w 12w ann				x		bl 12 w ann	(HbA1c)
Usher et al (2006) ⁹²	x		x	x	bl 4w 8w 12w quart	x		bl 4w 8w 12w quart	x	x (100)	unclear	
Barnett et al (2007) ⁷⁷	x	x	(x)	x	bl 4w 8w 12w 6monthly	x	x	bl 12w 6monthly	x	x (100)	bl 12w 6monthly	(NF) OGTT
Cahn et al (2008) ⁷⁸	x	x	x	x	bl (1m) (2m) 3m 6m ann	x			x	x (110)	bl (1m) (2m) 3m 6m ann	HbA1c
Elkis et al (2008) ⁸²	x	x	x	x	bl 4w 8w 12w trim ann (waist)	x	x	bl 12w ann	x	x (110)	bl 12w ann	OGTT

Saiz et al (2008) ⁸⁹	x	x	x		bl ann) bl 6m 12m 18m 24m	x		x		bl 6m 2yearly	
Salokangas et al (2008) ⁹⁰								x		bl	
Saravane et al (2008) ⁹¹	x	x	x	x	bl 4w 8w 12w trim ann	x	x	bl 8w ann	x	x (100)	bl 12w ann
De Hert et al (2009) ⁷⁹	x	x	x	x	bl 6w 12 w ann	x	x	bl 6w 12w ann	x	x (110)	bl 6w 12w ann (HbA1c)
Gotheffors et al (2010) ⁸³	x	x	x	x	bl 4w 8w 12w quart	x	x	bl 12w ann	x	x (110)	bl 12w ann OGTT
Fulfilling criterion	16	15	15	12		12	8		18	15	
n (%)	(89%)	(83%)	(83%)	(67%)		(67%)	(44%)		(100%)	(83%)	

Table DS5 Recommended measurements and proposed timing of assessments (*continued*).

Author (year)	CHOL	Cut-off values	Frequency	TRIG	Cut-off values	Frequency	HDL	Cut-off values	Frequency	Monitoring according to society guidelines
ADA/APA (2004) ⁷⁵	x		bl 12w every 5y	x			x		bl 12w every 5y	
Marder et al (2004) ⁸⁶	x	x		x	x		x	x		
Melkerson et al (2004) ⁸⁷	x			x						
Lambert et al (2004) ⁸⁴	(x)									x
Dinan et al (2004) ⁸¹										
De Nayer et al (2005) ⁸⁰	x	x		x	x		x	x		x
Poulin et al (2005) ⁸⁸	x			x			x	x		x
Amati et al (2006) ⁷⁶	x			x	x		x	x		
Lefevre et al (2006) ⁸⁵	x		bl 2yearly	x		bl 2yearly	x		bl 2yearly	
Usher et al (2006) ⁹²				x						
Barnett et al (2007) ⁷⁷	x	x		x	x		x	x		x
Cahn et al (2008) ⁷⁸	x	x		x	x		x	x		
Elkis et al (2008) ⁸²	x	x	bl 12w ann	x	x	bl 12w ann	x	x	bl 12w ann	x
Saiz et al (2008) ⁸⁹	x		bl 6m 2yearly	x		bl 6m 2yearly	x		bl 6m 2yearly	x
Salokangas et al (2008) ⁹⁰	x		bl	x		bl				
Saravane et al (2008) ⁹¹	x	x	bl 12w ann	x	x	bl 12w ann	x	x	bl 12w ann	x
De Hert et al (2009) ⁷⁹	x	x	bl 6w 12 w ann	x	x	bl 6w 12 w ann	x	x	bl 6w 12w ann	x
Gotheffors et al (2010) ⁸³	x	x	bl 12w ann	x	x	bl 12w ann	x	x	bl 12w ann	
Fulfilling criterion n (%)	16 (89%)	8 (44%)		16 (89%)	9 (50%)		13 (72%)	10 (56%)		8 (44%)

BMI, body mass index; BP, blood pressure; FGLU, fasting glucose; CHOL, cholesterol; TRIG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NF, non-fasting glucose; HbA1c, glycosylated haemoglobin; OGTT, oral glucose tolerance test; bl, baseline; w, weeks; m, months; quart, quarterly; ann, annually; hosp, when in hospital; (x): mentioned or optional.

Table DS6 Recommendations for additional somatic assessments over time.

Author (year)	MetS	Symptoms diabetes	DKA	Additional lab test	ECG	Additional investigations
ADA/APA (2004) ⁷⁵		x	x			
Marder et al (2004) ⁸⁶		x		Prolactin when symptoms	x	Cataract, myocarditis
Melkerson et al (2004) ⁸⁷		x	x			
Lambert et al (2004) ⁸⁴	(x)	x	x			
Dinan et al (2004) ⁸¹		x				
De Nayer et al (2005) ⁸⁰	atp	x	x			
Poulin et al (2005) ⁸⁸		x		Liver and thyroid function	x	
Amati et al (2006) ⁷⁶	atp	x		Prolactin	x	
Lefevre et al (2006) ⁸⁵						Myocarditis (clozapine), sexual function
Usher et al (2006) ⁹²						
Barnett et al (2007) ⁷⁷	idf	x	x			Cardiac evaluation mentioned
Cahn et al (2008) ⁷⁸	atp	x		Liver function, prolactin	x	Bladder, dental, monitor gastrointestinal complications, EEG
Elkis et al (2008) ⁸²	(x)	x				
Saiz et al (2008) ⁸⁹				Liver function, prolactin, thyroid function, toxicological screening, viral serology	x	Dental, sexual function
Salokangas et al (2008) ⁹⁰	(x)			thyroid function, toxicological screening	x	EEG, MRI
Saravane et al (2008) ⁹¹		x	x		x	cardiac complications
De Hert et al (2009) ⁷⁹		x			x	Monitor all CVD, technical investigation specified if patient has diabetes
Gotheffors et al (2010) ⁸³				Liver, renal and thyroid function, prolactin	x	COPD, dental
Fulfilling criterion n (%)	4 (22%)	12 (67%)	6 (33%)	7 (39%)	9 (50%)	10 56(%)

MetS, metabolic syndrome; DKA, diabetic ketoacidosis; ECG, electrocardiogram; atp: Adult Treatment Panel; idf, International Diabetes Federation; EEG, electroencephalogram; MRI, magnetic resonance imaging; COPD, chronic obstructive pulmonary disease; (x), mentioned but not specified.

Table DS7 Therapeutic and educational recommendations.

Author (year)	AP choice	AP switch	Psychoeducation patient	Psychoeducation family	Advice on physical activity	Advice on diet	Smoking cessation
ADA/APA (2004) ⁷⁵		x	x	x	x	x	
Marder et al (2004) ⁸⁶	x	x	x		x	x	
Melkerson et al (2004) ⁸⁷		x			x	x	x
Lambert et al (2004) ⁸⁴			x	x	x	x	x
Dinan et al (2004) ⁸¹					Specific	x	
De Nayer et al (2005) ⁸⁰	x	x	x	x	Specific	x	x
Poulin et al (2005) ⁸⁸			x		Specific	Specific	
Amati et al (2006) ⁷⁶			x	x	x	x	x
Lefevre et al (2006) ⁸⁵		x	x	x	x	x	x
Usher et al (2006) ⁹²			x		x	x	x
Barnett et al (2007) ⁷⁷	x	x	x		x	x	
Cahn et al (2008) ⁷⁸		x	x		Specific	Specific	x
Elkis et al (2008) ⁸²			x	x	specific	x	
Saiz et al (2008) ⁸⁹			x	x	x	x	x
Salokangas et al (2008) ⁹⁰					x		
Saravane et al (2008) ⁹¹	x	x	x		Specific	Specific	
De Hert et al (2009) ⁷⁹	x	x	x	x	Specific	Specific	x
Gotheffors et al (2010) ⁸³	x	x	x	x	x	x	
Fulfilling criterion n (%)	6 (33%)	10 (56%)	15 (83%)	9 (50%)	18 (100%)	17 (94%)	9 (50%)

Table DS7 Therapeutic and educational recommendations (*continued*).

Author (year)	Treatment diabetes	Treatment hypertension	Treatment lipids	Referral for advice and treatment	Education mental health staff	Education GP	Education somatic specialists
ADA/APA (2004) ⁷⁵	x	x	x	x	x		x
Marder et al (2004) ⁸⁶	x		x	x			
Melkerson et al (2004) ⁸⁷	x		x				
Lambert et al (2004) ⁸⁴	x			x			
Dinan et al (2004) ⁸¹				(x)			
De Nayer et al (2005) ⁸⁰	x		x	x	x	x	
Poulin et al (2005) ⁸⁸	x						
Amati et al (2006) ⁷⁶	x		x	x			
Lefevre et al (2006) ⁸⁵	x			x			
Usher et al (2006) ⁹²				x			
Barnett et al (2007) ⁷⁷	x	x	x	x	x		
Cahn et al (2008) ⁷⁸	x	x	x				
Elkis et al (2008) ⁸²	x		x				
Saiz et al (2008) ⁸⁹				x	x	x	x
Salokangas et al (2008) ⁹⁰							
Saravane et al (2008) ⁹¹	x	x	x	x			
De Hert et al (2009) ⁷⁹	x	x	x	x	x	x	x
Gotheffors et al (2010) ⁸³	x	x	x	x	x	x	x
Fulfilling criterion n (%)	14 (78%)	6 (33%)	11 (61%)	12 (67%)	6 (33%)	4 (22%)	4 (22%)

AP, antipsychotic; RF, risk factors for cardiovascular disease and diabetes; GP, general practitioner; (x), mentioned but not specified.